RxDoctor Payments Data

Sylvia Dold, DO

Rheumatology · Gainesville, GANPI 1326088873

Payments from drug & device makers

$3,450in general payments, 2019–2025

Across 230 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$558
  • UCB, Inc.$293
  • Novartis$250
  • Boehringer Ingelheim$204
  • Johnson & Johnson$110
  • plus $248 from 10 others

What the payments were for

  • Food & beverage$3,36397%
  • Education$873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,450 in reported general payments places this provider in the 40th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$173,037
Medicare patients
352
Services billed
6,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab58$641,440
Enbrel SureclickEtanercept23$315,218
Orencia ClickjectAbatacept21$213,319
RinvoqUpadacitinib22$199,193
Humira(Cf)Adalimumab18$187,901
BenlystaBelimumab21$101,894
Actemra ActpenTocilizumab29$97,915
KevzaraSarilumab18$95,416
OtezlaApremilast12$95,323
Xeljanz XrTofacitinib Citrate13$74,783
HumiraAdalimumab11$74,183
ActemraTocilizumab11$52,773
Hydroxychloroquine Sulfate476$24,794
PlaquenilHydroxychloroquine Sulfate11$8,076
MethotrexateMethotrexate Sodium291$7,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Humira$1,787$461,27851 claims
GSKBenlysta$53$101,89421 claims
SanofiKevzara$40$95,41618 claims
AmgenOtezla$558$95,32312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →